Uterine Papillary Serous Carcinoma

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Clinical obstetrics and gynecology

• Publication date

  2011-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/GRF.0b013e318218c755PMID 21508697
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Uterine papillary serous carcinoma: epidemiology, pathogenesis and management

  2010influential reference
• A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study.

  2009cited by this paper
• Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review.

  2009influential reference
• Platinum/taxane‐based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma

  2009cited by this paper
• An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC).

  2009cited by this paper
• Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes.

  2009cited by this paper
• An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study.

  2008cited by this paper
• The utility and cost effectiveness of preoperative computed tomography for patients with uterine malignancies.

  2008cited by this paper
• Role of cytoreduction in stage III and IV uterine papillary serous carcinoma.

  2007cited by this paper
• Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: a phase II study of the Gynecologic Oncology Group.

  2006cited by this paper
• Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.

  2006cited by this paper
• Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.

  2005cited by this paper
• Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study.

  2005cited by this paper
• Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study.

  2005cited by this paper
• Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study.

  2004cited by this paper
• Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study.

  2004cited by this paper
• A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study.

  2004influential reference
• Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.

  2004influential reference
• Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma.

  2000influential reference
• A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study.

  1996cited by this paper
• Uterine Serous Carcinoma A Morphologically Diverse Neoplasm With Unifying Clinicopathologic Features

  1992cited by this paper
• Two pathogenetic types of endometrial carcinoma.

  1983cited by this paper

• The role of noncoding RNAs in rare gynecological cancers.

  2025cites this paper
• Ultra-processed food intake and risk of ovarian and endometrial cancer in the NIH-AARP cohort: a prospective cohort analysis: Ultra-processed food, ovarian & endometrial cancer.

  2025cites this paper
• Molecular comparison reveals distinct transcriptomic differences between uterine carcinosarcoma and papillary serous carcinoma distinguishable by DNA damage.

  2025cites this paper
• Atlas of Tumor and Tumor Microenvironment Cells of Lymphovascular Space Invasion (LVSI) in High-Grade Serous Endometrial Adenocarcinoma: A Case Study

  2024cites this paper
• Minimally Invasive and Emerging Diagnostic Approaches in Endometrial Cancer: Epigenetic Insights and the Promise of DNA Methylation

  2024cites this paper
• Endometrial cancer with positive sentinel lymph nodes: pathologic characteristics of metastases as predictors of extent of lymphatic dissemination and prognosis

  2024cites this paper
• Mapping three-dimensional intratumor proteomic heterogeneity in uterine serous carcinoma by multiregion microsampling

  2024cites this paper
• Hereditary Women’s Cancer: Management and Risk-Reducing Surgery

  2023cites this paper
• Narrative review on the evolving role of HER2/neu targeting in uterine serous cancers

  2023cites this paper
• Comparative Study Between Superficial and Deep Myometrial Invasion in Endometrial Cancer Type 1 in Relation to Regional Lymph Nodes Metastasis

  2023cites this paper
• Counselling and management of women with genetic predisposition to gynaecological cancers.

  2023cites this paper
• A review of basic to clinical targeted therapy and immunotherapy in uterine serous cancer

  2023cites this paper
• Upgrading Treatment and Molecular Diagnosis in Endometrial Cancer—Driving New Tools for Endometrial Preservation?

  2023cites this paper
• The clinico pathological features and survival in serous endometrial cancers

  2023cites this paper
• Determination of the Cancer Genome Atlas (TCGA) Endometrial Cancer Molecular Subtypes Using the Variant Interpretation and Clinical Decision Support Software MH Guide

  2023cites this paper
• Pharmacological targeting of polyamine and hypusine biosynthesis reduces tumour activity of endometrial cancer

  2022cites this paper
• Molecular analysis of endometrial serous carcinoma reveals distinct clinicopathologic and genomic subgroups.

  2022cites this paper
• Does Lymph Node Dissection Impact Adjuvant Treatment or Survival Outcomes in High-Risk Endometrial Cancers?

  2022cites this paper
• Minimally Invasive Compared With Open Surgery in High-Risk Endometrial Cancer

  2022cites this paper
• Targeted Therapies in the Treatment of Uterine Serous Carcinoma

  2022cites this paper
• Importance of p53, bcl-2 genes in uterine body cancer and their role in prediction

  2022cites this paper
• Preoperative ultrasound assessment of myometrial invasion in endometrial cancer and prediction of surgical stage

  2022cites this paper
• Evaluation of a Patient With Non-Myoinvasive Uterine Serous Carcinoma Confined to a Polyp and Positive Peritoneal Washings With Somatic ARHGAP35 and KRAS Mutations

  2022cites this paper
• Immunosuppressive tumor microenvironment in Uterine Serous Carcinoma via CCL7 signal with myeloid-derived suppressor cells.

  2022cites this paper
• EZH2 and Endometrial Cancer Development: Insights from a Mouse Model

  2022cites this paper
• Bone Marrow-Derived Cells in Endometrial Cancer Pathogenesis: Insights from Breast Cancer

  2022cites this paper
• Is Diagnostic Hysteroscopy Safe for the Investigation of Type II Endometrial Cancer? A Retrospective Cohort Analysis.

  2021cites this paper
• Initial surgical management of bulky malignant type II tumors of the endometrium by a robotic approach

  2021cites this paper
• Oncologic safety of minimally invasive surgery in non-endometrioid endometrial cancer.

  2021cites this paper
• MicroRNA profiling in a case-control study of African American women with uterine serous carcinoma.

  2021cites this paper
• Development of a seven-gene tumor immune microenvironment prognostic signature for high-risk grade III endometrial cancer

  2021cites this paper
• Matched-pair Analysis for Survival Endpoints Between Women With Early-stage Uterine Carcinosarcoma and Uterine Serous Carcinoma

  2021cites this paper
• A case of synchronous serous ovarian cancer and uterine serous endometrial intraepithelial carcinoma

  2021cites this paper
• The current evidence for the use of minimally-invasive surgery in endometrial cancer

  2021cites this paper
• The presence of an endometrioid component does not alter the clinicopathologic profile or survival of patients with uterine serous cancer: A gynecologic oncology group (GOG/NRG) study of 934 women.

  2021cites this paper
• Exploring Prognosis-Associated Biomarkers of Estrogen-Independent Uterine Corpus Endometrial Carcinoma by Bioinformatics Analysis

  2021cites this paper
• Preoperative neutrophil-to-lymphocyte, platelet-to-lymphocyte and monocyte-to-lymphocyte ratio as a prognostic factor in non-endometrioid endometrial cancer

  2021cites this paper
• Clinical significance of homologous recombination deficiency score testing in endometrial Cancer.

  2021cites this paper
• Incidence of omental metastasis in uterine serous carcinoma: study protocol for a systematic review and meta-analysis

  2021cites this paper
• The role of lymphadenectomy in patients with stage III&IV uterine serous carcinoma: Results of multicentric Turkish study.

  2021cites this paper
• Trastuzumab with carboplatin/paclitaxel for treatment of advanced stage and recurrent uterine papillary serous carcinoma: A cost-effectiveness analysis.

  2020cites this paper
• Identification of prognostic immune-related genes in the tumor microenvironment of endometrial cancer

  2020cites this paper
• Uterine serous carcinoma: Molecular features, clinical management, and new and future therapies.

  2020cites this paper
• The prominent value of apparent diffusion coefficient in assessing high-risk factors and prognosis for patients with endometrial carcinoma before treatment

  2020cites this paper
• Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assays

  2020cites this paper
• Expression of ER/PR Receptor, Her-2/neu, Ki67 and p53 in Endometrial Carcinoma: Clinicopathological Implication and Prognostic Value

  2020cites this paper
• Comprehensive lymphadenectomy and survival prediction in uterine serous cancer patients after surgery: A population-based analysis.

  2020cites this paper
• UTERİN SERÖZ KARSİNOM VE UTERİN BERRAK HÜCRELİ KARSİNOM TANISI ALAN HASTALARDA KLİNİKOPATOLOJİK ÖZELLİKLERİN VE SAĞ KALIM SONUÇLARININ KARŞILAŞTIRILMASI Comparison Of Clinicopathologic Characteristics And Survivals In Patients With Uterine Serous And Clear Cell Carcinoma

  2020cites this paper
• Estrogen receptor expression in complex and/or atypical endometrial hyperplasia and endometrial adenocarcinoma

  2020influential citation
• Pathogenesis and Clinical Management of Uterine Serous Carcinoma

  2020cites this paper
• Risk of endometrial cancer among women with benign ovarian tumors - A Danish nationwide cohort study.

  2020cites this paper
• Should the risk for uterine cancer influence decision making for prophylactic hysterectomy in BRCA1/2 mutated patients- a systematic review and meta-analysis.

  2020cites this paper
• COMPARISON OF OVERALL SURVIVAL AND DISEASE-FREE SURVIVAL IN SEROUS ENDOMETRIAL CANCER AND UTERINE CARCINOSARCOMA

  2019influential citation
• Molecular markers in uterine serous cancer: Correlation between endometrial biopsy and hysterectomy specimens

  2019cites this paper
• Increasing BMI is associated with both endometrioid and serous histotypes among endometrial rather than ovarian cancers: a case-to-case study.

  2019cites this paper
• Analysis of the outcome of patients with stage IV uterine serous carcinoma mimicking ovarian cancer

  2019cites this paper
• Does tumor size have prognostic value in patients undergoing lymphadenectomy in endometrioid-type endometrial cancer confined to the uterine corpus?

  2019cites this paper
• Nicotinamide N-methyltransferase expression and its association with phospho-Akt, p53 expression, and survival in high-grade endometrial cancer

  2019cites this paper
• Establishment of the Prognosis Predicting Signature for Endometrial Cancer Patient

  2019cites this paper
• Sentinel lymph node mapping alone compared to more extensive lymphadenectomy in patients with uterine serous carcinoma.

  2019cites this paper
• Gynecologic Disorders in the Older Woman

  2019cites this paper
• Value of p53 and estrogen receptors immunohistochemical staining in endometrial carcinoma

  2019cites this paper
• Sentinel lymph node biopsy in endometrial cancer

  2018cites this paper
• Are the uterine serous carcinomas underdiagnosed? Histomorphologic and immunohistochemical correlates and clinical follow up in high-grade endometrial carcinomas initially diagnosed as high-grade endometrioid carcinoma

  2018cites this paper
• Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: A NCI clinical trials planning meeting report.

  2018cites this paper
• Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers

  2018cites this paper
• Prognostic Factors of Uterine Serous Carcinoma—A Multicenter Study

  2018cites this paper
• An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer.

  2018cites this paper
• Impact of lower uterine segment involvement in type II endometrial cancer and the unique mutational profile of serous tumors

  2018cites this paper
• Cancer Antigen 125 Levels are Significantly Associated With Prognostic Parameters in Uterine Papillary Serous Carcinoma

  2018cites this paper
• Uterine cancer in Jewish Israeli BRCA1/2 mutation carriers

  2018cites this paper
• Uterine Cancer

  2018cites this paper
• Novel approaches to early detection of endometrial cancer

  2017cites this paper
• Current strategies in the diagnosis of endometrial cancer

  2017cites this paper
• Factors prognostic of survival in advanced-stage uterine serous carcinoma.

  2017cites this paper
• Endometrial Cancer: Advanced Stage

  2017cites this paper
• DECLARATION OF ORIGINALITY

  2017cites this paper
• Minimally Invasive Approach in Type II Endometrial Cancer: Is It Wise and Safe?

  2017cites this paper
• Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer

  2017cites this paper
• Diagnostik und Therapie des Endometriumkarzinoms

  2017cites this paper
• Study on the prognostic value of p53 and PTEN immunomarkers for endometrial cancer using immunohistochemistry

  2017cites this paper
• Significance of venous thromboembolism in women with uterine carcinosarcoma.

  2017cites this paper
• Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo

  2016cites this paper
• Follow-up strategies for women with endometrial cancer after primary treatment

  2016cites this paper
• Metastatic papillary serous uterine cancer presenting as a rash

  2016cites this paper
• Critical role for BRCA1 expression as a marker of chemosensitivity response and prognosis.

  2016cites this paper
• Uterine serous carcinoma: a historic evaluation of therapy.

  2016cites this paper
• Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations.

  2016cites this paper
• Adjuvant Pelvic Radiation Therapy±Vaginal Brachytherapy in Patients With High-risk Stage I or Stage II Uterine Papillary Serous, Clear Cell, and High-grade Endometrioid Carcinoma

  2016cites this paper
• AXL modulates extracellular matrix protein expression and is essential for invasion and metastasis in endometrial cancer

  2016cites this paper
• Clinical Significance of Homologous Recombination Deficiency Score Testing in Endometrial Cancer

  2016influential citation
• Survival outcomes of obese patients in type II endometrial cancer: Defining the prognostic impact of increasing BMI.

  2016cites this paper
• Therapeutic Modalities in Early-Stage Uterine Papillary Serous Carcinomas, Carcinosarcomas, Clear-Cell and Mixed Histology Carcinomas: Treatment of Choice Is Combined Chemotherapy and Radiation

  2016cites this paper
• Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis.

  2016cites this paper
• Lympho-vascular space invasion indicates advanced disease for uterine papillary serous tumors arising from polyps.

  2015cites this paper
• Adjuvant treatment, tumour recurrence and the survival rate of uterine serous carcinomas: a single-institution review of 62 women

  2015cites this paper
• Possible therapeutic implication of PD-L1/PD-1 axis in endometrial cancer

  2015cites this paper
• LVSI Indicates an Advanced Disease for Uterine Papillary Serous Tumors Arising from Polyps

  2015cites this paper
• Is a More Comprehensive Surgery Necessary in Patients With Uterine Serous Carcinoma?

  2015cites this paper
• Polymerase ɛ (POLE) mutations in endometrial cancer: Clinical outcomes and implications for Lynch syndrome testing

  2015cites this paper